An independent Food and Drug Administration (FDA) advisory panel votes to recommend approval of Moderna’s mRNA-based influenza vaccine for older adults. The panel’s recommendation comes after reviewers assessed the vaccine’s benefits and risks for adults in two age groups: people aged 50 to 64 and those 65 and older. According to reporting, the advisors voted unanimously, with a 9–0 result, concluding that the benefits outweigh the risks for the proposed use. Moderna’s product is described as an mRNA flu shot, branded as mFlusiva in one account, and the company is seeking FDA authorization for administration to the older-age population covered by the recommendation. The advisory panel’s action is a step in the regulatory process; FDA typically considers such recommendations as it moves toward a final decision on whether to approve the vaccine. If approved, it would mark a first availability of an mRNA-based flu vaccine for the older adults group addressed by the panel’s vote.